| 000 | 01753 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517120630.0 | ||
| 264 | 0 | _c20170221 | |
| 008 | 201702s 0 0 eng d | ||
| 022 | _a1676-5680 | ||
| 024 | 7 |
_a10.4238/gmr.15038734 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNabinger, D D | |
| 245 | 0 | 0 |
_aInfluence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia. _h[electronic resource] |
| 260 |
_bGenetics and molecular research : GMR _cSep 2016 |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAmoxicillin _xadministration & dosage |
| 650 | 0 | 4 | _aBrazil |
| 650 | 0 | 4 |
_aClarithromycin _xadministration & dosage |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2C19 _xgenetics |
| 650 | 0 | 4 |
_aDyspepsia _xdrug therapy |
| 650 | 0 | 4 | _aEndoscopy, Gastrointestinal |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHelicobacter Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHelicobacter pylori _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInactivation, Metabolic _xgenetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOmeprazole _xadministration & dosage |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 700 | 1 | _aMazzoleni, L E | |
| 700 | 1 | _aSander, G B | |
| 700 | 1 | _aMazzoleni, F | |
| 700 | 1 | _aOsório, M C | |
| 700 | 1 | _aKlein, M G | |
| 700 | 1 | _aRech, T F | |
| 700 | 1 | _aBasso da Silva, L | |
| 700 | 1 | _ade Moraes, G S | |
| 700 | 1 | _aCristovam, R A | |
| 700 | 1 | _aNardelli, E F | |
| 700 | 1 | _aFrancesconi, C F M | |
| 700 | 1 | _aSimon, D | |
| 773 | 0 |
_tGenetics and molecular research : GMR _gvol. 15 _gno. 3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4238/gmr.15038734 _zAvailable from publisher's website |
| 999 |
_c26486812 _d26486812 |
||